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In this issue of Intensive Care Medicine, Finfer and
colleagues describe an important new clinical trial which
(re-)examines the effects of a not-so-new drug—recom-
binant human activated protein C (rhAPC)—on outcome
in sepsis [1]. This publication is important because it
describes—at an early phase—the basis for and protocol of
a study, which will hopefully not only clarify but also
potentially change clinical use of this drug. The decision to
inform the intensive care community of the trial right from
the beginning also motivates this editorial, which reviews
some aspects of the complexity of the relationship and
interactions in the triangle of three major players (but not
always ideal partners) involved in pertinent clinical
research: science, medicine and industry.
The primary objectives of each of the three stake-
holders are quite different. The pharmaceutical industry
wants to make profit, but is also very much interested in
bringing new products to the market (necessary for its
sustainable development) and in innovation (which
improves its image in the eyes of society). Science is
curiosity-driven, with the aim of furthering our under-
standing of human biology, physiology, and mechanisms
of disease, also to discover better ways to treat disease.
Finally, the objective of medicine is to help patients to get
better quickly and to recover a good quality of life.
Naturally, the patient and society cannot be left out.
They expect, if not cure, then the best possible care, and at
an acceptable price. Society and the public also expect the
major players in medical progress to demonstrate corpo-
rate responsibility, meeting the strictest ethical standards,
ensuring the protection of patients’ dignity and physical
integrity, and respecting the principle of distributive jus-
tice with regard to the limited resources available for
health care. This also includes sharing access to knowl-
edge and benefits from novel interventions.
There is still much that we do not know about sepsis. It
is a very complex syndrome, with many different pre-
sentations and several forms of clinical evolution, which
makes understanding it more difficult and a standard
approach to management elusive. Sepsis is also a good
example of the essential steps in ‘‘translational research’’.
More than for other diseases, our understanding of sepsis
has evolved because of multiple journeys from bedside to
bench and back. Many areas of basic science and a variety
of clinical specialties have contributed to major devel-
opments in the field. Fortunately, the role of industry has
not been limited to supporting the clinical aspects of
research and testing of new drugs or devices; the financial
support provided by industry for elucidation of basic
mechanisms has been significant. Active intellectual and
financial relationships between industry and its partners in
research and health care have brought significant progress
to science and patient care. However, there is a clear need
for better rules, improved disclosure and management
principles [2–4].
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Now, in their new clinical trial, Finfer and col-
leagues—all renowned specialists in the field of
intensive care—and representatives of industry have
seized a unique opportunity to make a model case, not
only for efficient collaboration, but also for providing
better overall transparency from the beginning of a
study to the very end, up through the publication of all
relevant results. Clinicians count on the complete
objectivity promised by investigators and industry, and
the availability of all results, to bring them desperately
needed clarification in the treatment of septic shock.
Ultimately, the ICU team wants a clear answer to the
question of which patients—if any—benefit from
rhAPC.
Mutual trust between medicine, science and industry is
essential but not free from conflicts of interest, since the
scientific community and industry depend on each other
to such a great extent [5]. Society and the media are
suspicious of collaborations between industry and the
medical and scientific communities; they often see con-
flicts of interest, which do not seem evident to those
directly involved. This mistrust results, for example, in
articles ‘‘accusing the drugmakers of deceiving the public,
manipulating doctors and putting profits before patients’’
[5]. It is up to medicine to convince all interested par-
ties—scientists, industry, and society—that it does the
best it can for the patient. Today society is more critical of
science and medicine when these seem not to respect the
limits set by common sense for transparency and financial
disclosures.
A good way to provide support for the industry–sci-
ence–medicine triangle in light of public (mis)trust is to
enforce guidelines established by neutral bodies, defining
good collaboration, conflicts of interests and integrity in
science. Such guidelines exist [6, 7], and the general
adherence to them must be made more widely known to
the public. At the same time, controlling has to be
improved and non-adherence must be clearly sanctioned.
Intensive care medicine is a young specialty, and
large-scale randomized controlled trials (RCTs) in this
domain have a very short history. Before the 1980’s,
practically no large RCTs were performed. By 1990, the
number of intensive care RCTs published annually had
reached 50 (PubMed search for ‘‘intensive care OR
critical care’’, ‘‘humans, randomized controlled trial’’),
and in 2000, for the first time more than 200 articles per
year could be found with these search terms. It is
therefore clear that the bulk of clinical intensive care
medicine practice is not evidence-based, but rather based
on physiological and pathophysiological concepts and
craftsmanship.
The quest for evidence-based treatments for critically
ill patients has led to proliferation of RCTs. Unfortu-
nately, most RCTs in intensive care medicine have
produced negative results, including increased mortality
from interventions expected to improve outcomes, and
non-reproducible results of trials that have changed clin-
ical practice [8–23]. Also, the design and interpretation of
several benchmark clinical RCTs have been questioned
and heavily debated [24–28].
The frustration of evidence-based medicine-driven
scientists and clinicians is not surprising, and it is
understandable that the intensive care medicine com-
munity may be ready to jump on any bandwagon
resulting from a single positive RCT. This frustration is
the likely explanation for the rapid acceptance and
widespread promotion of such single-center trial find-
ings as tight glucose control [22] and ‘‘early goal-
directed therapy’’ [29] in sepsis. In marked contrast to
this enthusiasm, the positive results from the PROW-
ESS study [17], a large, international multicenter RCT
on recombinant human activated protein C (rhAPC) in
sepsis, have been applied in clinical practice with
substantial hesitation, despite the high-profile publicity
and aggressive marketing surrounding the results and
the inclusion of the use of rhAPC in the (also contro-
versial) Surviving Sepsis Campaign treatment guidelines
[30].
What can explain this apparent reluctance to translate
into clinical practice the results of a large, international,
multicenter RCT, a prime example of the kind of evi-
dence praised by evidence-based medicine? Some would
argue that it is the costs. Yet, although costly in com-
parison to many common drugs, rhAPC is not
particularly expensive when compared to the overall
costs of intensive care or to use of such common
interventions as modern coronary artery stents. Others
would argue that the aggressive marketing may have
backfired. While these issues may certainly contribute, a
much more complex, and in fact reasonable, explanation
seems likely.
Intensive care clinicians are uncomfortable with the
specific problems related to RCTs in intensive care
patients with sepsis. Although it is a rapidly lethal
condition, sepsis is a syndrome rather than a well-
definable disease. The clinician recognizes the diversity
of clinical problems and comorbidities that are common
in patients with sepsis, and is likely to be reluctant and
uncomfortable in administering a drug with a broad
spectrum of biological effects and potentially serious,
even life-threatening side effects. It does not help that
the exact pathophysiological mechanisms of the expec-
ted benefits of rhAPC in sepsis are unclear and subject
to debate.
Not only clinicians but also regulatory authorities
seem to share this reluctance. The United States Food
and Drug Administration (FDA) approved rhAPC in the
midst of debate, and attached a severity score in the
drug’s label—an unprecedented concept, given that
severity scoring systems have never been validated for
this purpose. The European authorities also attached a
severity-of-disease indicator (organ system failure) in the
1951
label, and chose to give a time-limited approval, later
insisting that a confirmatory trial was necessary. This
has now resulted in the launch of the PROWESS-shock
study.
All this debate and controversy has finally had a
sobering effect on the translation of results from clin-
ical trials into clinical practice. In the era of large
‘‘pivotal’’ RCTs, it is often forgotten that reproduc-
ibility is the crucial issue in evaluating any scientific
evidence. In order to justify fundamental changes in
current practice, multiple positive RCTs are necessary.
When the results of all or most of the available
research points in the same direction, it is much more
likely that the finding also holds true when the inter-
vention is applied outside of strictly controlled clinical
trials. In the end, it is up to the clinician to ask: How
well do the study setting and patient selection represent
those patients that I am considering for the interven-
tion? How well does the known risk-benefit profile
apply to my patient population [31]? Am I convinced
that there is more benefit than potential harm?
Meanwhile, the sponsor of the PROWESS-shock study
must be painfully aware of the specific problems related
to large RCTs in the critical care setting: patients with
rapidly lethal conditions, the poorly definable syndromes
rather than diseases present in most septic patients, the
difficulties in assessing the severity of such syndromes,
the interacting treatments, and the at best marginally
understood interactions between physiology, pathophysi-
ology, and concomitant treatments. If the results of the
PROWESS-shock trial do not confirm the results of the
original PROWESS trial, it is unlikely that industry will
continue to expend money and effort on evaluating
rhAPC in sepsis. This would have potential far-reaching
consequences in terms of the readiness of industry in
general to invest in critical care trials.
In addition to efficacy, one of the most important
concerns with rhAPC has been safety, especially the risk
of bleeding. Efficacy trials may not reveal the full risk
profile of a drug. The risks of bleeding may be higher in
clinical practice, where the spectrum of patients may be
wider than in the strictly controlled clinical trial setting. It
is also conceivable that different combinations of drugs
interfering with the coagulation system may modify the
additional risk of bleeding caused by rhAPC. The avail-
able data suggest that the risks of bleeding that
accompany the use of rhAPC may indeed be higher than
originally estimated from the RCTs.
Concerns over safety issues not revealed in RCTs
powered for efficacy is nothing new. Of the new drugs
submitted to the FDA from 1993 to 2004 and approved by
2005, 11 registered drugs were withdrawn from the
market for safety reasons in the US [32]. The current
study adds a sizeable group of patients with the highest
severity of illness, whereas the previous studies covered a
wide spectrum of severity of illness; it is therefore very
well conceivable that the side effect profile may be
different.
Safety monitoring in rapidly lethal diseases is difficult,
and the PROWESS-shock trial focuses on a patient sub-
group with especially lethal disease. Considering the
safety concerns related to the use of rhAPC, maximizing
safety monitoring would have been preferable. This
would include—in addition to the ‘‘normal’’ procedure of
submitting the study to a data safety monitoring com-
mittee—an unblinded safety assessment. The current
study design allows the data safety monitoring committee
to request an unblinded review, but such a review is not
mandatory. Many intensivists—including the authors of
this editorial—are convinced that the disadvantages of
blinded evaluation outweigh the advantages. In our view,
unblinded safety monitoring, independent of the request
of the data safety monitoring committee, should have
been included in the protocol for the PROWESS-shock
trial (see for example [33]).
One of the major issues in industry-sponsored research
is the scientific community’s lack of access to the data. In
many instances, investigators’ access to the data is
restricted as well, and the pharmaceutical industry has
even been known to restrict investigators’ rights to pub-
lish. Meanwhile, the scientific community has a track
record of naivety and willingness to sign contracts that
restrict their rights. Despite the fact that scientific journals
commonly request authors to confirm that they have had
full access to the data and that they agree with the analysis
and interpretation, true full and unrestricted access to
industry-supported study data is rather a rare exception.
This is a major concern for many reasons, including, for
example, independent verification of study results, pub-
lication bias of negative results, and lack of possibility to
address potential safety issues in accumulating data, just
to name a few.
The investigators of the PROWESS-shock trial have
made a laudable effort to introduce an improved model
of collaboration between science, medicine and indus-
try. This approach could help to get us out of the
image of a Bermuda triangle, where benefits of research
and resources for health care disappear in a black hole
or the wallets of a few. All parties involved have taken
major steps. The ultimate goal is a platform with open
access for the entire scientific community. Only by
working together—with trust and transparency—can we
hope to solve the riddle of sepsis in the decades to
come.
1952
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